DMYD-B:STO
Diamyd Medical AB
SEKÂ 1.01
arrow_downward
-0.39%(-0.0040) 1D
Oct 20, 5:29:52 PM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEKÂ 1.02
High
SEKÂ 1.03
Low
SEKÂ 1.00
Mkt. cap
153.60M
Avg. vol.
842.57K
Volume
124.16K
52-wk high
SEKÂ 17.88
52-wk low
SEKÂ 0.90
EPS
-SEKÂ 1.76
Shares outstanding
134.00M
No. of employees
42
Open
SEKÂ 1.02
High
SEKÂ 1.03
Low
SEKÂ 1.00
Mkt. cap
153.60M
Avg. vol.
842.57K
Volume
124.16K
52-wk high
SEKÂ 17.88
52-wk low
SEKÂ 0.90
EPS
-SEKÂ 1.76
Shares outstanding
134.00M
No. of employees
42
News stories
From web sources and news partners
BigGo Finance
·
26 minutes ago
Dow Jumps 530 Points as Health Care Surges to Record; Nasdaq Stalls on AI Spending Worries
Yahoo Finance
·
1 hour ago
Update: US Equity Indexes Mixed as Weakness in Communications Services, Technology Restrains Nasdaq Composite
marketscreener.com
·
1 hour ago
US Equity Indexes Mixed as Weakness in Communications Services, Technology Restrains Nasdaq Composite
FXEmpire
·
4 hours ago
Dow Jones Price Forecast: Bulls Eye 57,000 as October 6 Low Remains Key
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB